Martin Health System Unveils Xenex Germ-Zapping Robot™ more

Jesuit High School Alumnus Donates Xenex Germ-Zapping Robot to His Alma Mater more

BiO2 Medical Announces Successful Completion of the Angel® Catheter Pivotal Clinical Trial more

Xenex Awarded Premier, Inc. Group Purchasing Contract to Offer Germ-Zapping Robot™ Room Disinfection Technology to Premier Member Hospitals more

SA bioscience companies strike new deal to expand scope of stem cell research more

TFS Corporation share price flat despite soaring earnings more

TFS Corporation doubles quarterly profit more

Innovation makes money grow on trees more

Xenex Germ-Zapping Robot™ Destroys Ebola Virus & Anthrax Spores in New Study Performed at Texas Biomed Biosafety Level 4 Lab more

Indian sandalwood oil producer ramps up production to supply new markets more

Cytocentrics Inc. wins Innovator Award at recent event more

Key Opinion Leader (KOL) Calls for New Standard to Close Port-Site Hernias in Lap and Robotic Surgeries more

Surgical Site Infections Decrease 100% after Trinity Medical Center Implements Infection Control Bundle more

Court Order Requires Tru-D to Cease False and Misleading Statements more

Merck and DNAtrix Announce Phase 2 Immuno-Oncology Collaboration more

San Antonio biotech firm CEO is heading west more

Sandalwood grower smells a fortune more

Explore the UV LED market that is expected to reach USD 369.58 million by 2020 more

Ten Life Sciences Companies to Watch in Central Texas more

San Antonio’s Xenex signs national contract with HealthTrust more

Xenex Signs Agreement with HealthTrust; Germ-Zapping Robots™ Added to the HealthTrust Portfolio more

Benzac® Intensive Spot Treatment Named Best Acne Treatment of 2015 by HEALTH Magazine more

neoSurgical® Reports Commercial Milestone of 2000 US Procedures more

Launch of latest hyaluronic acid based filler range more

Galderma Laboratories Announces the Nationwide Availability of Benzac® more

BioMed SA Celebrates 10th Anniversary more

TFS completes US pharma acquisition more

Finally, Good News for Anyone Looking for a Gentle Acne Treatment more

4th Peer-Reviewed Study to Credit Xenex Germ-Zapping Robots for Infection Rate Decrease more

A pair of biotech VCs take aim at raising SA’s status more

BiO2 Medical raises $4M for device that prevents embolism more

How SA landed Cytocentrics more

Sandalwood firm sticks to forecasts more

Two New Studies Show Decrease in Hospital Acquired Infections after Xenex Germ-Zapping Robots Used for Room Disinfection more

Xenex Offers Industry’s First HAI Reduction Guarantee; Multiple Hospitals Report Decrease in Infection Rates When Using Xenex Germ-Zapping Robots for Room Disinfection more

Xenex to expand sales of ‘germ-zapping robots’ to more European nations more

West Australian Indian sandalwood oil producer purchases American drug companies more

Sandlewood grower to buy US-based pharmaceutical firms more

Cytocentrics has big plans for San Antonio more

TFS Corporation Limited jumps on acquisitions: What you need to know more

Australian firm acquires multiple San Antonio bioscience companies; Deal could be worth $270 million more

TFS To Acquire ViroXis And Santalis Pharma - Quick Facts more

DNAtrix Collaborators Present Data on a Novel Oncolytic Adenovirus Expressing OX40 Ligand that Promotes Antitumor Immunity more

San Antonio expected to become bigger global research player as result of Cytocentrics deal more

Cytocentrics Wins $1 Million Incentive and Warm Welcome to San Antonio more

San Antonio approves major incentive deal to lure German biotech firm more

German Biosciences Company Relocating Headquarters to San Antonio more

Cytocentrics looking to relocate HQ to San Antonio, create 300 jobs more

Cytocentrics CEO: Biotech company passed up bigger financial offers to move to San Antonio more

Milwaukee VA center cleared to use germ-zapping robots more

GAO Affirms VA Contract for Mercury-Free UV Disinfection System, Milwaukee VA Hospital Orders Xenex Full-Spectrum™ Germ-Zapping Robots™ more

Pivotal Investigation of BiO2 Medical's Angel Catheter Exceeds Enrollment Expectations more

Alcyone Lifesciences and DNAtrix Enter Clinical Collaboration for Brain Cancer more

Here’s why these 4 companies are soaring higher today more

Harvard gets wood more

2 Works for You helps teen diagnosed with brain cancer denied access to experimental treatment more

Harvard University sees the good oil in NT sandalwood plantation more

San Antonio bioscience companies to team up on critical research more

Germ-zapping R2-D2 look-alike works at Renown more

Are TFS Corporation Limited shares an absolute bargain? more

Med tech start-up exits Bank of Ireland Seed Fund with US$21m valuation more

Galway-based NeoSurgical exits Kernel Capital more

Xenex sells Germ-Zapping robot to Iowa nonprofit hospital more

Broadlawns Employs Xenex Robot to Eradicate Germs more

Benzac® Acne Solutions Premieres Its First-Ever “Insta-Dramedy” Webseries more

Sandalwood grower enlists F1 star more

StemBioSys closes $8m in funding to help launch its stem cell culture system more

Irish start-up neoSurgical has just signed an exclusive distribution deal for the US market. But, as founder and CEO Barry Russell explains, it has taken persistence and courage to get the company this far more

Xenex exporting hospital-cleaning robots to Europe more

Xenex Germ-Zapping Robots Arrive in Spain; Clece Chooses Xenex for Hospital Disinfection more

Takes $8M to Build Homes For Stem Cells more

San Antonio biomedical company StemBioSys scores major funding more

Lexington Fire Department chosen to conduct trial on new EMS Equipment more

Xenex Rebuts Clorox Attack Following NAD Press Release more

San Antonio’s Xenex files lawsuit against Cloroxn more

Lexington Fire Dept. Among First In Kentucky Testing New Device more

Here’s why today is a good day to buy TFS Corporation Limited shares more

Over-the-counter (OTC) remedies rescue consumers from skin and health issues that are—at the time—more pressing than fine lines and wrinkles more

Germ-zapping Dalek-like robots trialed at King’s Lynn’s Queen Elizabeth Hospital to reduce the spread of infection more

Seven Women Run Tech Startups in San Antonio to Watch more

UV light from robots disinfects hospital rooms more

TFS rises on upgraded guidance more

Biological assets boost valuation for TFS more

NPSF Patient Safety Coalition Welcomes Xenex more

UV Disinfection Equipment Market is Expected to Reach $2.8 Billion by 2020 – Allied Market Research more

Scent of success more

BiO2 Medical Begins Enrollment for the Pivotal Investigation of the Angel® Catheter more

Baptist Health's new germ-zapping robots use untraviolet light as a disinfectant more

Baptist Health adds "cleaning robots" more

The Only Full Spectrum™ Pulsed Xenon UV Disinfection System more

Benzac® Acne Solutions Launches in the US more

State of health care: Xenex CEO says company is winning war against deadly infections more

The Health Cell to present event focusing on San Antonio’s health care and biosciences sector more

San Antonio developing biotech executive talent more

Xenex’s latest funding exceeds expectations, expands international opportunities more

San Antonio bioscience company Xenex secures major funding more

Germ-Zapping Robot Makes House Call for Texas Baby more

Hospitals name their disinfecting robots to add personality more

The robot will clean up now: More hospitals buying automated systems to reduce infections more

New Study Shows Pulsed Xenon UV Light Effective in Reducing C. diff, MRSA and VRE in the Hospital Environment more

Forecast: Three San Antonio biomedical companies to watch in 2015 more

Here’s why these 4 stocks are soaring higher today more

Sandalwood the good oil for US funds more

Oil Investment Could Put A Smile On The Faces Of Harvard Students more

Harvard takes stake in TFS more

Aromatherapy at home can be easy more

TFS up on US acne product launch more

BiO2 Medical Receives IDE Approval to Initiate Pivotal Investigation of the Angel® Catheter more

StemBioSys Inc. to Present at Biotech Showcase™ 2015 more

Galderma Laboratories Launches Its First Over-the-Counter Acne Regimen, Benzac® Acne Solutions

World’s Leading Dermatology Company Fights Acne by Combining Proven Acne Fighting Medicine with Breakthrough Natural Ingredients

FT. WORTH, Texas--(BUSINESS WIRE)--Galderma Laboratories, L.P., maker of Cetaphil® and the #1 prescription topical acne brand, today announced the launch of Benzac® Acne Solutions, its first-ever, over-the-counter (OTC) acne regimen. Benzac treats stubborn acne and prevents new breakouts from forming with salicylic acid, while pharmaceutical-grade East Indian Sandalwood Oil calms and soothes the skin. In a clinical study, 91% of people saw improvement in their acne in two weeks when using the new 3-step Benzac Acne Solutions, which includes the Benzac Skin Balancing Foaming Cleanser, Benzac Intensive Spot Treatment and Benzac Blemish Clearing Hydrator.

“Building on our long-standing heritage in prescription acne treatments and commitment to providing innovative dermatological solutions, Galderma is offering Benzac as an effective, non-irritating solution for the nearly 100% of teens and up to 50 million Americans who suffer from mild-to-moderate acne”

“Unlike many other acne treatments that don’t live up to their claims, Benzac is game changing in that it is clinically proven to help acne sufferers see predictable, smooth and luminous skin while minimizing irritation,” says board-certified dermatologist Dr. Jeanine Downie. “Benzac is also the only skincare line to use East Indian Sandalwood Oil, which has been used for thousands of years in Eastern medicine and is known to have antibacterial and anti-inflammatory properties and soothes the skin.”

In addition to salicylic acid, Benzac also contains Kakadu plum, an antioxidant super fruit known for having the highest natural concentration of vitamin C, to brighten the skin; lemon myrtle, a natural astringent, to help reduce excess oil; and the mineral zinc, which is shown to act as a barrier against skin moisture loss.

“Building on our long-standing heritage in prescription acne treatments and commitment to providing innovative dermatological solutions, Galderma is offering Benzac as an effective, non-irritating solution for the nearly 100% of teens and up to 50 million Americans who suffer from mild-to-moderate acne,” said Miles Harrison, Vice President and General Manager for Self Medication at Galderma Laboratories, L.P. “We want to help patients avoid the frustration of experimenting and skin irritation from multiple OTC products. If you haven’t seen improvement in your skin within two weeks of using the Benzac regimen, you should talk to your dermatologist about prescription treatment options.”

Safe for sensitive skin, Benzac is dermatologist tested, non-comedogenic (won’t clog pores) and free of artificial fragrances and dyes. It is not tested on animals. Benzac cartons are 100% recyclable, and the key ingredient in the regimen, East Indian Sandalwood Oil, is sustainably sourced.

The Benzac Complete Acne Solutions Regimen ($36.24 for the 3-step regimen)* and individual products Benzac Skin Balancing Foaming Cleanser ($14.92 for 6.0 FL OZ),* Benzac Intensive Spot Treatment ($16.84 for 0.5 FL OZ)* and Benzac Blemish Clearing Hydrator ($16.84 for 1.0 FL OZ)* are available at major retailers nationwide and online, including Benzac.com and Amazon.com.

About Galderma
Galderma is a global company founded in 1981 committed to delivering innovative medical solutions to meet the dermatological needs of people throughout their lifetime while serving healthcare professionals around the world. The company has 34 wholly-owned affiliates with a worldwide network of distributors and more than 5,000 employees. Galderma’s extensive product portfolio is available in 80 countries and treats a range of dermatological conditions including: acne, rosacea, onychomycosis, psoriasis & steroid-responsive dermatoses, pigmentary disorders, skin cancer and medical solutions for skin senescence.

With approximately 19% of revenues invested each year to discover and develop new products and access innovative technologies, the company is one of the world’s leading investors in dermatology R&D. Five state-of-the-art R&D centers and five manufacturing sites are dedicated to providing a wide range of innovative medical solutions which meet the highest standards of safety and efficacy.

Source: http://www.businesswire.com

January 5th 2015 back